Extracellular proteolysis: New paradigms for an old paradox

Journal of Laboratory and Clinical Medicine

Volumn 134, Issue 4, 1999, Pages 341-351

  Owen, Caroline A ^a   Campbell, Edward J ^b  

^a UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0033215368     PISSN: 00222143     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-2143(99)90148-8     Document Type: Article

References (109)

1. 1. Owen CA, Campbell EJ. Proteinases. In: Haslett C, Evans T, editors. Adult respiratory distress syndrome. London: Chapman & Hall; 1995.
2. 2. Bruce MC, Poncz L, Klinger JD, Stern RC, Tomashefski JF Jr. Dearborn DG. Biochemical and pathologic evidence for proteolytic destruction of lung connective tissue in cystic fibrosis. Am Rev Respir Dis 1985;132:529-35.
3. 3. Power C, O'Connor CM, Macfarlane D, et al. Neutrophil collagenase in sputum from patients with cystic fibrosis. Am J Respir Crit Care Med 1994;150:818-22.
4. 1-proteinase inhibitor, elastase activity, and lung disease severity in cystic fibrosis. Am Rev Respir Dis 1993;148:1665-70.
5. 5. Shapiro SD. The pathogenesis of emphysema: the elastase:antielastase hypothesis 30 years later. Proc Assoc Am Physicians 1995;107:346-52.
6. 6. Hautamaki RD, Kobayashi DK, Senior RM, Shapiro SD. Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice. Science 1997;277:2002-4.
7. 7. Murphy G, Hembry RM. Proteinases in rheumatoid arthritis. J Rheum 1992;32(suppl):61-4.
8. 8. Larbre J-P, Moore AR, Da Silva JAP, Iwamura H, Ioannou Y, Willoughby DA. Direct degradation of articular cartilage by rheumatoid synovial fluid: contribution of proteolytic enzymes. J Rheumatol 1994;21:1796-801.
9. 9. Moses MA. The regulation of neovascularization by matrix metalloproteinases and their inhibitors. Stem Cells 1997;15: 180-9.
10. 10. Bell WR. The fibrinolytic system in neoplasia. Semin Thromb Hemost 1996;22:459-78.
11. 11. Cornelius LA, Nehring LC, Harding E, et al. Matrix metalloproteinases generate angiostatin: effects on neovascularization. J Immunol 1998;161:6845-52.
12. 12. Travis J, Salvesen GS. Human plasma proteinase inhibitors. Annu Rev Biochem 1983;52:655-709.
13. 13. Campbell EJ, Campbell MA. Pericellular proteolysis by neutrophils in the presence of proteinase inhibitors: effects of substrate opsonization. J Cell Biol 1988;106:667-76.
14. 14. Campbell EJ, Senior RM, McDonald JA, Cox DL. Proteolysis by neutrophils. Relative importance of cell-substrate contact and oxidative inactivation of proteinase inhibitors in vitro. J Clin Invest 1982;70:845-52.
15. 15. Rice WG, Weiss SJ. Regulation of proteolysis at the neutrophil-substrate interface by secretory leukoprotease inhibitor. Science 1990;249:178-81.
16. 16. Beatty K, Bieth J, Travis J. Kinetics of association of serine proteinases with native and oxidised alpha-1-proteinase inhibitor and alpha-1-antichymotrypsin. J Biol Chem 1980; 255:3931-4.
17. 17. Carp H, Janoff A. Inactivation of bronchial mucous proteinase inhibitor by cigarette smoke and phagocyte-derived oxidants. Exp Lung Res 1980;1:225-37.
18. 18. Carp H, Janoff A. In vitro suppression of serum elastase-inhibitory capacity by reactive oxygen species generated by phagocytosing polymorphonuclear leukocytes. J Clin Invest 1979;63:793-7.
19. 1-proteinase inhibitor in vitro. J Clin Invest 1980; 66:987-95.
20. 20. Reddy VY, Desrochers PE, Pizzo SV, et al. Oxidative dissociation of human alpha 2-macroglobulin tetramers into dysfunctional dimers. J Biol Chem 1994;269:4683-91.
21. 21. Meyer KC, Zimmerman J. Neutrophil mediators, Pseudomonas, and pulmonary dysfunction in cystic fibrosis. J Lab Clin Med 1993;121:654-61.
22. 22. Cochrane CG, Spragg R, Revak SD. Pathogenesis of the adult respiratory distress syndrome. Evidence of oxidant activity in bronchoalveolar lavage fluid. J Clin Invest 1983; 71:754-61.
23. 23. Wong PS, Travis J. Isolation and properties of oxidised alpha-1-proteinase inhibitor from human rheumatoid synovial fluid. Biochem Biophys Res Commun 1980; 96:1449-54.
24. 2-macroglobulin differentially regulates receptor binding by cytokines/growth factors: implications for tissue injury and repair mechanisms in inflammation. J Immunol 1998;161:4356-65.
25. 1-proteinase inhibitor. Am J Physiol 1994; 10:L593-611.
26. 1-protease inhibitor in bronchoalveolar lavage fluid. Am Rev Respir Dis 1985;131:79-85.
27. 27. Gadek JE, Fells GA, Crystal RG. Cigarette smoking induces functional antiprotease deficiency in the lower respiratory tract of humans. Science 1979;206:1315-6.
28. 28. Stone PJ, Calore JD, McGowan SE, Bernardo J, Snider GL, Franzblau C. Functional alpha-1-protease inhibitor in the lower respiratory tract of cigarette smokers is not decreased. Science 1983;221:1187-9.
29. 29. Sires UI, Murphy G, Welgus HG, Senior RM. Matrilysin is much more efficient than other metalloproteinases in the proteolytic inactivation of alpha 1-antitrypsin. Biochem Biophys Res Commun 1994;204:613-20.
30. 30. Desrochers PE, Mookhtiar K, Van Wart HE, Hasty KA, Weiss SJ. Proteolytic inactivation of alpha 1-proteinase inhibitor and alpha 1-antichymotrypsin by oxidatively activated human neutrophil metalloproteinases. J Biol Chem 1992;267:5005-12.
31. 1-antitrypsin in cystic fibrosis bronchopulmonary secretions. Pediatr Pulmonol 1989;7:12-7.
32. 32. Wu K, Urano T, Ihara H, et al. The cleavage and inactivation of plasminogen activator inhibitor type 1 by neutrophil elastase: the evaluation of its physiologic relevance in fibrinolysis. Blood 1995;86:1056-61.
33. 1 proteinase inhibitor by thiol proteinases. Biochem J 1977;163:639-41.
34. 34. Sponer M, Nick H-P, Schnebli H-P. Different susceptibility of elastase inhibitors to inactivation by proteinases from Staphylococcus aureus and Pseudomonas aeruginosa. Biol Chem Hoppe-Seyler 1991;372:963-70.
35. 35. Okada Y, Watanabe S, Nakanishi I, et al. Inactivation of tissue inhibitor of metalloproteinases by neutrophil elastase and other serine proteinases. FEBS Lett 1988;229:157-60.
36. 1-proteinase inhibitor) in knee-joint synovial fluid from patients with rheumatoid arthritis. Biochem Soc Trans 1990;18:898-9.
37. 1-antichymotrypsin by neutrophils in arthritic joints. Arthritis Rheum 1993;36:168-80.
38. 1-proteinase inhibitor in infected bronchial secretions from patients with cystic fibrosis. Eur Respir J 1991;4:40-9.
39. 39. Rao CN, Ladin DA, Liu YY, Chilukuri C, Hou ZZ, Woodley DT. Alpha 1-antitrypsin is degraded and non-functional in chronic wounds but intact and functional in acute wounds. The inhibitor protects fibronectin from degradation by chronic wound fluid enzymes. J Invest Dermatol 1995;105:572-8.
40. 40. Wright SD, Silverstein SC. Phagocytosing macrophages exclude proteins from zones of contact with targets. Nature 1984;309:359-61.
41. 41. Teitelbaum SL, Tondravi MM, Ross FP. Osteoclasts, macrophages, and the molecular mechanisms of bone resorption. J Leukocyte Biol 1997;61:381-8.
42. 42. Campbell EJ, Campbell MA. Proteolysis by neutrophils while in contact with substrate: incomplete protection of substrate by proteinase inhibitors. In: Mittman C, Taylor JC, editors. Pulmonary emphysema and proteolysis (vol II). New York: Academic Press; 1987. p. 235-44.
43. 43. Chamba A, Afford SC, Stockley RA, Burnett D. Extracellular proteolysis of fibronectin by neutrophils: characterization and the effects of recombinant cytokines. Am J Respir Cell Mol Biol 1990;4:330-7.
44. 44. Briscoe DM, Cotran RS. Role of leukocyte-endothelial cell adhesion molecules in renal inflammation: in vitro and in vivo studies. Kidney Int 1993;44:S27-34.
45. 45. Haller H, Eichhorn J, Pieper K, Gobel U, Luft FC. Circulating leukocyte integrin expression in Wegener's granulomatosis. J Am Soc Nephrol 1996;7:40-8.
46. 46. Stegeman CA, Tervaert JW, Huitema MG, deJong PE, Kallenberg CG. Serum levels of soluble adhesion molecules intercellular adhesion molecule 1, vascular cell adhesion molecule 1, and E-selectin in patients with Wegener's granulomatosis. Arthritis Rheum 1994;37:1228-35.
47. 47. Mrowka C, Sieberth HG. Circulating adhesion molecules ICAM-1, VCAM-1, and F-selectin in systemic vasculitis: marked differences between Wegener's granulomatosis and systemic lupus erythematosis. Clin Invest 1994;72:762-8.
48. 48. Pall AA, Howie AJ, Adu D, et al. Glomerular vascular cell adhesion molecule-1 expression in renal vasculitis. J Clin Pathol 1996;49:238-42.
49. 49. Jaeschke H, Smith CW. Mechanisms of neutrophil-induced parenchymal cell injury. J Leukocyte Biol 1997;61:647-53.
50. 50. Takeyama K, Agusti C, Ueki I, Lausier J, Cardell LO, Nadel JA. Neutrophildependent goblet cell degranulation: role of membrane-bound elastase and adhesion molecules. Am J Physiol 1998;275:L294-302.
51. 51. Owen CA, Campbell MA, Sannes PL, Boukedes SS, Campbell EJ. Cell-surface-bound elastase and cathepsin G on human neutrophils. A novel, non-oxidative mechanism by which neutrophils focus and preserve catalytic activity of serine proteinases. J Cell Biol 1995;131:775-89.
52. 52. Owen CA, Campbell MA, Boukedes SS, Campbell EJ. Inducible binding of cathepsin G to the cell surface of neutrophils: a mechanism for mediating extracellular proteolytic activity of cathepsin G. J Immunol 1995;155:5803-10.
53. 53. Owen CA, Campbell MA, Boukedes SS, Campbell EJ. Cytokines regulate membrane-bound leukocyte elastase on neutrophils: a novel mechanism for effector activity. Am J Physiol 1997;272:L385-93.
54. 54. Csernok E, Ernst M, Schmitt W, Bainton DF, Gross WL. Activated neutrophils express proteinase 3 on their plasma membrane in vitro and in vivo. Clin Exp Immunol 1994;95: 244-50.
55. 55. Heiple JM, Ossowski L. Human neutrophil plasminogen activator is localized in specific granules and is translocated to the cell surface by exocytosis. J Exp Med 1986;164:826-40.
56. 56. Vassalli JD, Wohlwend A, Belin D. Urokinase-catalyzed plasminogen activation at the monocyte/macrophage cell surface: a localized and regulated proteolytic system. Curr Top Microbiol Immunol 1992;181:65-86.
57. 57. Partridge CA, Phillips PG, Niedbala MJ, Jeffrey JJ. Localization and activation of type IV collagenase/gelatinase at endothelial focal contacts. Am J Physiol 1997;272:L813-22.
58. 58. Corcoran ML, Emmert-Buck MR, McClanahan JL, Pelina-Parker M, Stetler-Stevenson WG. TIMP-2 mediates cell surface binding of MMP-2. Adv Exp Med Biol 1996;389: 295-304.
59. 59. Ward RV, Atkinson SJ, Reynolds JJ, Murphy G. Cell surface-mediated activation of progelatinase A: demonstration of the involvement of the C-terminal domain of progelatinase A in cell surface binding and activation of progelatinase A by primary fibroblasts. Bioehem J 1994;304:263-9.
60. 60. Brooks PC, Stromblad S, Sanders LC, et al. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin αvβ3. Cell 1996;85: 683-93.
61. 61. Allen DH, Tracy PB. Human coagulation factor V is activated to the functional cofactor by elastase and cathepsin G expressed at the monocyte surface. J Biol Chem 1995;270: 1408-15.
62. 62. Owen CA, Campbell EJ. Angiotensin II generation at the cell surface of activated neutrophils: novel cathepsin G-mediated catalytic activity that is resistant to inhibition. J Immunol 1998;160:1436-43.
63. 63. Ellis V, Wun T-C, Behrendt N, Ronne E, Dano K. Inhibition of receptor-bound urokinase by plasminogen-activator inhibitors. J Biol Chem 1990;265:9904-8.
64. 64. Gross WL, Csernok E, Flesch BK. 'Classic' anti-neutrophil cytoplasmic autoantibodies (cANCA), 'Wegener's autoantigen' and their immunopathogenic role in Wegener's granulomatosis. J Autoimmun 1993;6:171-84.
65. 65. Porges AJ, Redecha PB, Kimberly WT, Csernok E, Gross WL, Kimberly RP. Anti-neutrophil cytoplasmic antibodies engage and activate human neutrophils via Fcgamma RIIa. J Immunol 1994;153:1271.
66. 66. Falk RJ, Terrell RS, Charles LA, Jennette JC. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci USA 1990;87:4115-9.
67. 67. Charles L, Caldas M, Falk R, Terrell R, Jennette JC. Antibodies against granule proteins activate neutrophils in vitro. J Leukocyte Biol 1991;50:539-46.
68. 68. Chen W-T. Membrane proteases: roles in tissue remodeling and tumour invasion. Curr Opin Cell Biol 1992;24947: 802-9.
69. 69. Cockett MI, Birch ML, Murphy G, Hart IR, Docherty AJP. Metalloproteinase domain structure, cellular invasion and metastasis. Biochem Soc Trans 1994;22:55-7.
70. 70. Rabbani SA. Metalloproteases and urokinase in angiogenesis and tumor progression. In Vivo 1998;12:135-42.
71. 71. Knudsen BS, Silverstein RL, Leung LLK, Harpel PC, Nachman RL. Binding of plasminogen to extracellular matrix. J Biol Chem 1986;261:10765-71.
72. 72. Allan JA, Docherty AJP, Barker PJ, Huskisson NS, Reynolds JJ, Murphy G. Binding of gelatinases A and B to type-1 collagen and other matrix components. Biochem J 1995;309:299-306.
73. 73. Hembry RM, Bagga MR, Murphy G, Henderson B, Reynolds JJ. Animal model. Rabbit models of arthritis: immunolocalization of matrix metalloproteinases and tissue inhibitor of metalloproteinase in synovium and cartilage. Am J Pathol 1993;143:628-42.
74. 74. Damiano VV, Tsang A, Kucich U, et al. Immunolocalization of elastase in human emphysematous lungs. J Clin Invest 1986;78:482-93.
75. 75. Morrison HM, Welgus HG, Stockley RA, Burnett D, Campbell EJ. Inhibition of human leukocyte elastase bound to elastin: relative ineffectiveness and two mechanisms of inhibitory activity. Am J Respir Cell Mol Biol 1990;2: 263-9.
76. 1-proteinase inhibitor and bronchial inhibitor. Potent inhibition of elastin-bound elastase by bronchial inhibitor. Biochem J 1986;238:269-73.
77. 77. Bartholomew J, Lowther DA. Receptor mediated binding of leukocyte elastase by chondrocytes. Arthritis Rheum 1987; 30:431-8.
78. 78. Kawabata K, Moore AR, Willoughby DA. Impaired activity of protease inhibitors towards neutrophil elastase bound to human articular cartilage. Ann Rheum Dis 1996;55:248-52.
79. 1-proteinase inhibitor: an in vitro model of enzyme inhibition in the joint space. Rheumatol Int 1987;7:133-8.
80. 80. Velvart M, Fehr K. Degradation in vivo of articular cartilage in rheumatoid arthritis and juvenile chronic arthritis by cathepsin G and elastase from polymorphonuclear leukocytes. Rheumatol Int 1987;7:195-202.
81. 81. Curci JA, Liao S, Huffman MD, Shapiro SD, Thompson RW. Expression and localization of macrophage elastase (matrix metalloproteinase-12) in abdominal aortic aneurysms. J Clin Invest 1998;102:1900-10.
82. 82. Kainulainen V, Wang H, Schick C, Bernfield M. Syndecans, heparan sulfate proteoglycans, maintain the proteolytic balance of acute wound fluids. J Biol Chem 1998;273:11563-9.
83. 83. Savill J. Apoptosis in resolution of inflammation. J Leukocyte Biol 1997;61:375-80.
84. 84. Sepper R, Konttinen YT, Buo L, et al. Potentiative effects of neutral proteinases in an inflamed lung: relationship of neutrophil procollagenase (proMMP-8) to plasmin, cathepsin G and tryptase in bronchiectasis in vivo. Eur Respir J 1997;10:2788-93.
85. 85. Sepper R, Konttinen YT, Ding Y, Takagi M, Sorsa T. Human neutrophil collagenase (MMP-8), identified in bronchiectasis BAL fluid, correlates with severity of disease. Chest 1995;107:1641-7.
86. 86. Owen CA, Campbell EJ. The cell biology of leukocyte-mediated proteolysis. J Leukocyte Biol 1999;65:137-50.
87. 87. Lee CT, Fein AM, Lippmann M, Holtzman M, Kimbel P, Weinbaum G. Elastolytic activity in pulmonary lavage fluid from patients with adult respiratory-distress syndrome. N Engl J Med 1981;304:192-6.
88. 88. Cochrane CG, Spragg RG, Revak SD, Cohen AB, McGuire WW. The presence of neutrophil elastase and evidence of oxidation activity in bronchoalveolar lavage fluid of patients with adult respiratory distress syndrome. Am Rev Respir Dis 1983;127:S25-7.
89. 89. Christner P, Fein A, Goldberg S, Lippmann M, Abrams W, Weinbaum G. Collagenase in the lower respiratory-tract of patients with adult respiratory-distress syndrome. Am Rev Respir Dis 1985;131:690-5.
90. 90. Weiland J, Davis WB, Holter J, Mohammed J, Dorinsky P, Gadek J. Lung neutrophils in the adult respiratory distress syndrome. Am Rev Respir Dis 1986;133:218-25.
91. 91. Delclaux C, D'Ortho M-P, Delacourt C, et al. Gelatinases in epithelial lining fluid of patients with adult respiratory distress syndrome. Am J Physiol 1997;272:L442-51.
92. 92. Nordstrom D, Lindy O, Konttinen YT, et al. Cathepsin G and elastase in synovial fluid and peripheral blood in reactive and rheumatoid arthritis. Clin Rheumatol 1996;15:35-41.
93. 93. Sorsa T, Konttinen YT, Lindy O, et al. Collagenase in synovitis of rheumatoid arthritis. Semin Arthritis Rheum 1992;22:44-53.
94. 94. Beekman B, van El B, Drijfhout JW, Ronday HK, TeKoppele JM. Highly increased levels of active stromelysin in rheumatoid synovial fluid determined by a selective fluorogenic assay. FEBS Lett 1997;418:305-9.
95. 95. Koolwijk P, Miltenburg AMM, van Erck MGM, et al. Activated gelatinase-B (MMP-9) and urokinase-type plasminogen activator in synovial fluids of patients with arthritis. Correlation with clinical and experimental variables of inflammation. J Rheumatol 1995;22:385-93.
96. 96. Campbell EJ. Preventive therapy of emphysema: lessons from the elastase model. Am Rev Respir Dis 1986;134:435-7.
97. 97. Liou TG, Campbell EJ. Non-isotropic enzyme-inhibitor interactions: a novel non-oxidative mechanism for quantum proteolysis by human neutrophils. Biochemistry 1995;34: 16171-7.
98. 98. Liou TG, Campbell EJ. Quantum proteolysis resulting from release of single granules by neutrophils: a novel, non-oxidative mechanism of extracellular proteolytic activity. J Immunol 1996;157:2624-31.
99. 1-antitrypsin deficiency: clinical and physiological features in heterozygotes of type Pi SZ. A survey by the British Thoracic Association. Br J Dis Chest 1983;77:28-34.
100. 100. Hutchison DCS. Natural history of alpha-1-protease inhibitor deficiency. Am J Med 1988;84(suppl 6A):3-12.
101. 101. Turino GM, Barker AF, Brantly ML, et al. Clinical features of individuals with Pi *SZ phenotype of alpha 1-antitrypsin deficiency. Alpha 1-antitrypsin deficiency registry study group. Am J Respir Crit Care Med 1996;154:1718-25.
102. 1-antitrypsin (AAT) deficiency [abstract]. Thorax 1997;52(suppl 6):A16.
103. 1-antitrypsin deficiency. J Clin Invest. In press. J Clin Invest 1999;104:337-44.
104. 104. Rudolphus A, Heinzel-Wieland R, Vincent VA, et al. Oxidation-resistant variants of recombinant antileucoprotease are better inhibitors of human-neutrophil-elastase-induced emphysema in hamsters than natural recombinant antileucoprotease. Clin Sci 1991;81:777-84.
105. 105. Gossage JR, Kuratomi Y, Davidson JM, Lefferts PL, Snapper JR. Neutrophil elastase inhibitors, SC-37698 and SC-39026, reduce endotoxin-induced lung dysfunction in awake sheep. Am Rev Respir Dis 1993;147:1371-9.
106. 106. Ahn CM, Sandler H, Glass M, Saldeen T. Effect of a synthetic leukocyte elastase inhibitor on thrombin-induced pulmonary edema in the rat. Exp Lung Res 1993; 19:125-35.
107. 1-antitrypsin. Am J Respir Crit Care Med 1998;158:49-59.
108. 1-antitrypsin deficiency? Eur Respir J 1997;10:2260-3.
109. 109. Vender RL. Therapeutic potential of neutrophil-elastase inhibition in pulmonary disease. J Invest Med 1997;44: 531-9.